Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
170 CHF | -2.30% | -2.86% | -15.42% |
Dec. 01 | AbbVie to Buy Cancer-focused ImmunoGen for $10.1 Billion | MT |
Nov. 21 | Kepler Cheuvreux Lowers Price Target on HBM Healthcare Investments, Maintains Buy Recommendation | MT |
Evolution of the average Target Price on HBM Healthcare Investments AG
Price target over the last 5 years
History : Analyst Recommendations
e0a3bdf6b5baac.7b_FBOCWjUBtCBGS0ZVWHa-FMlzuDlcu5GZ3A6Ow0Uw.udnzZtbRvRIiQ0HQndMuS_ewUwmITwB9iFYTTerFmQWii69q1PHSIy9tYg~1e092ab1d50e2bd6bbe2bce040043805
Analysts' Consensus
Sell
Buy

Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
170CHF
Average target price
236CHF
Spread / Average Target
+38.82%
High Price Target
236CHF
Spread / Highest target
+38.82%
Low Price Target
236CHF
Spread / Lowest Target
+38.82%
Consensus detail
Consensus revision (last 18 months)
Analysts covering HBM Healthcare Investments AG
Kepler Capital Markets |
Trading Rating :
Investor Rating :
ESG Refinitiv :
D+
EPS Revisions
Annual profits - Rate of surprise
- Stock
- Equities
- Stock HBM Healthcare Investments AG - Swiss Exchange
- Consensus HBM Healthcare Investments AG